NurExone Biologic Inc. Emerges as a Promising Investment Opportunity in Biotechnology
TORONTO and TEL AVIV, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV:…
News
NurExone Biologic Inc. Emerges as a Promising Investment Opportunity in Biotechnology
TORONTO and TEL AVIV, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV:…
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
Topline trial results expected mid-March 2023 NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Acer…
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
Topline trial results expected mid-March 2023 NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Acer…
Cerevance Expands Series B Financing with Additional $51 Million
Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s…
Cerevance Expands Series B Financing with Additional $51 Million
Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s…
Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards
MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a…
Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards
MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a…
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
– Q-Code assigned to CIMERLI® for Medicare claims processing effective for dates of service on…
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
– Q-Code assigned to CIMERLI® for Medicare claims processing effective for dates of service on…
Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical…
Williams Appoints Carri Lockhart to Board of Directors
TULSA, Okla.–(BUSINESS WIRE)–Williams (NYSE: WMB) today announced that its Board of Directors has appointed Carri…
Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study
— Post hoc analyses found a statistically significant reduction in the duration of flu infection…
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate…
Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults
Based on Type C guidance requested and received from the U.S. Food and Drug Administration…
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease
Topline results including safety and proof-of-mechanism data expected in third quarter of 2023 CHARLOTTESVILLE, Va….
Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update
First subject enrolled into the OPMD clinical development program HAYWARD, Calif., Feb. 13, 2023 (GLOBE…
Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis
If Approved Later This Year, Nyxol Could be the Only Commercially Available Eye Drop for…
Amarin Shareholders Invited to Webcast with Board and Management Team
— Board and Management Team to Answer Shareholder Questions — DUBLIN, Ireland and BRIDGEWATER, N.J.,…
BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”…